Indoco Remedies Ltd

Indoco Remedies Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 06 Dec 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 25 April 2026, providing investors with an up-to-date view of the stock’s fundamentals, returns, and technical outlook.

Indoco Remedies Ltd commenced trading on 15 April 2026 with a notable gap up, opening 9.05% higher than its previous close, signalling a strong start and positive market sentiment despite its current 'Strong Sell' rating by MarketsMOJO.

Indoco Remedies Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 06 Dec 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 14 April 2026, providing investors with the latest insights into its performance and outlook.

Indoco Remedies Ltd has exhibited a subtle shift in its technical momentum, moving from a bearish stance to a mildly bearish trend, reflecting a complex interplay of technical indicators. Despite a modest day gain of 1.70%, the pharmaceutical small-cap continues to face headwinds amid mixed signals from MACD, RSI, moving averages, and other momentum oscillators, underscoring a cautious outlook for investors.

Indoco Remedies Ltd witnessed a significant gap up at the opening bell on 8 April 2026, surging by 5.52% to touch an intraday high of Rs 204.5. This strong start underscores a positive market sentiment despite the stock’s prevailing technical challenges and a recent downgrade in its mojo rating.

Indoco Remedies Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 06 Dec 2025. However, the analysis and financial metrics presented here reflect the stock’s current position as of 03 April 2026, providing investors with the latest insights into the company’s performance and outlook.

The Sensex advanced 2.76% on 1 Apr 2026, yet Indoco Remedies Ltd outpaced the broader market with a 7.83% gain, reaching an intraday high of Rs 178.7. This 6.23-percentage-point outperformance over the Pharmaceuticals & Biotechnology sector’s 2.07% rise signals a distinctly stock-specific rally rather than a mere market tailwind.

For the fifth consecutive session, Indoco Remedies Ltd closed lower, slipping to a fresh 52-week low of Rs 166.75 on 30 Mar 2026. This marks a near 10% decline over the past three days, underscoring persistent selling pressure despite a broader market that has shown some resilience.

While the broader market shows signs of recovery, Indoco Remedies Ltd has continued its downward trajectory, hitting a fresh 52-week low of Rs 173.35 on 27 Mar 2026. This decline comes amid a sharp underperformance relative to its sector and benchmark indices, raising questions about the underlying factors weighing on the stock.

While the broader market shows signs of recovery, Indoco Remedies Ltd has slipped to a fresh 52-week low of Rs 180.85 on 24 Mar 2026, extending its recent downward trajectory amid persistent financial headwinds and sector underperformance.

Indoco Remedies Ltd’s share price declined to a fresh 52-week low of Rs.187 on 23 March 2026, marking a significant milestone in the stock’s ongoing downward trajectory. This new low reflects persistent challenges faced by the company amid broader market weakness and sectoral pressures.

Indoco Remedies Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 06 Dec 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 23 March 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Indoco Remedies Ltd has recently touched a 52-week low, closing just 1.65% above its lowest price of Rs 188, marking a significant decline in the stock’s valuation over the past year. This development comes amid a backdrop of persistent financial headwinds and subdued market performance within the Pharmaceuticals & Biotechnology sector.

Indoco Remedies Ltd has reached a new 52-week low, with its stock price dropping to Rs.188.9 today, marking a significant decline amid broader market pressures and company-specific financial concerns.

Indoco Remedies Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 06 Dec 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 12 March 2026, providing investors with the latest insights into its performance and outlook.

Indoco Remedies Ltd’s share price declined sharply to a fresh 52-week low of Rs.189.25 today, marking a significant milestone in the stock’s ongoing downward trajectory. This new low reflects persistent challenges faced by the company amid a broader market downturn and sector-specific pressures.

Indoco Remedies Ltd’s stock declined to a fresh 52-week low of Rs.194.4 today, marking a significant milestone in its ongoing downward trajectory. The pharmaceutical company’s shares have been under pressure, reflecting a series of financial and market challenges that have weighed on investor sentiment and overall performance.